title: [Primary non-Hodgkin's lymphomas of the central nervous system. Still more questions than answers in the treatment?].
abstract: The optimal treatment of primary non-Hodgkin"s lymphomas of the central nervous system is still under discussion. Systemic treatment is compromised by the blood-brain barrier which is impermeable to several cytostatic agents. For several years, the standard treatment has been methotrexate-based chemotherapy followed by CNS-radiotherapy. However, this combination therapy may be complicated by later neurotoxicity. Intensive chemotherapy followed by autologous stem-cell transplantation is a new promising treatment approach without increased CNS-toxicity.
authors.affiliation: Herlev Hospital, Medicinsk Haematologisk Afdeling L, Herlev. peboha01@herlevhosp.kbhamt.dk
authors.forename: Per Boye
authors.initials: PB
authors.lastname: Hansen
authors.forename: Morten Krogh
authors.initials: MK
authors.lastname: Jensen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents